NP0014-5
UKKi007-B
General#
Donor Information#
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 45-49 |
| Ethnicity | Caucasian, German |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes |
|
| Non-disease associated phenotypes |
|
| Family history | de novo mutation |
| Is the medical history available upon request? | No (can be retreived upon request) |
| Is clinical information available? | Not available |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA2629512 |
Ethics#
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold a copy of the SIGNED Donor Consent Form? | No |
| If you do not hold the SIGNED Donor Consent Form, do you know who does? | No |
| If you do not hold the SIGNED Donor Consent Form, have you obtained a copy of the unsigned Donor Consent Form from the holder? | Yes |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent pertain to a specific research project? | No |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| an academic institution? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
| How may genetic information associated with the cell line be accessed? |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | Yes |
| Does consent permit access to medical records of the donor? | Yes |
| Please describe how access is provided: |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation#
General |
|
| Source cell type |
fibroblast of dermis |
| Source cell origin |
zone of skinAny portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
|
| Age of donor (at collection) | 45-49 |
| Collected in | 2009 |
| Passage number reprogrammed | P3 |
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Genes | |
| Is the used vector excisable? |
No |
| Absence of reprogramming vector(s)? |
Unknown |
| Reprogramming vectors silenced? | |
| Vector map | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | human ESC morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
| Surface coating | Vitronectin |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| SSEA-4 |
Yes |
|
|
|||
| TRA1-80 |
Yes |
|
|
Morphology pictures
Brighfield image of NP0014-5 colony at day 3 post-thaw at higher mahnification; 32x objective
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| HAND1 |
Yes |
| VIMENTIN |
Yes |
| BMP4 |
Yes |
| GATA4 |
No |
| DCN |
Yes |
| PECAM1 (CD31) |
Yes |
| PDGF |
Yes |
In vitro spontaneous differentiation
| Marker | Expressed |
| SOX17 |
Yes |
| FOXA2 |
No |
| GSC |
Yes |
| GATA6 |
Yes |
| CXCR4 |
Yes |
| PITX1 |
Yes |
| MYH6, alpha myosin heavy chain |
Yes |
| MLC2v, myosin light chain 2v |
Yes |
| ACTN2, cardiac alpha actinin |
Yes |
| RYR2 |
Yes |
In vitro spontaneous differentiation
| Marker | Expressed |
| PAX6 |
Yes |
| Sox1 |
Yes |
| B-TUBULIN |
Yes |
| NEUROD1 |
Yes |
| HES5 |
Yes |
| FOXG1 |
No |
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Not done |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
33
|
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
XY
Karyotyping method:
Molecular karyotyping using using OmniExpress Exome Chip
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
SNP-genotyping using OmniExpress Exome Chip
|
Login to share your feedback, experiences or results with the research community.